Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Infectious Diseases

Show all topics

DOI

10.1016/s1473-3099(21)00396-0

License

other-oa